Sanofi aims for Nexviazyme approval in younger Pompe disease patients
Sanofi’s Nexviazyme (avalglucosidase alfa) could be set for approval in younger children with Pompe disease after the Phase III Baby-COMET…
Metabolic Disorders
-
-
ADA26: retatrutide delivers unprecedented weight loss in Phase III TRIUMPH-1
On 6 June, at the 86th Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, findings from…
-
ECRD 2026: Europe’s rare disease bottleneck is funding rather than science
Rare disease R&D investment is outpacing the broader biotech market, while the pipeline of innovative therapies continues to deepen. With…
-
ECO 2026: tirzepatide shows potential for T1D treatment
During the 2026 European Congress on Obesity (ECO) in Istanbul, a meta-analysis was presented analysing the use of tirzepatide, a…
-
ECO 2026: gut hormone signals differ in T1D with obesity
At the 2026 European Congress on Obesity (ECO) in Istanbul, researchers presented a small observational study assessing fasting peptide YY…
-
ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition
On 12 May 2026, at the 33rd European Congress on Obesity in Istanbul, Türkiye, findings from the Phase 3a REDEFINE-1…
-
ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
On 28 March, at the American College of Cardiology (ACC) 75th Annual Scientific Session & Expo in New Orleans, Louisiana,…
-
ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D
Type 2 diabetes (T2D) and heart health have a complex and dependent relationship. New data presented at ACC 2026 suggests…
-
Novo sues Hims & Hers despite Wegovy pill offering U-turn
Hims & Hers has abandoned plans to sell a compounded version of Novo Nordisk’s Wegovy (semaglutide) pill, though Novo and…
-
FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint
US Food and Drug Administration (FDA) Commissioner Marty Makary said the agency would target the mass-marketing of unapproved drugs amid…
